NCT07655817 Oral Versus Intravenous Magnesium on Emergence Delirium
| NCT ID | NCT07655817 |
| Status | Recruiting |
| Phase | Phase 2, Phase 3 |
| Sponsor | Tanta University |
| Condition | Magnesium |
| Study Type | INTERVENTIONAL |
| Enrollment | 360 participants |
| Start Date | 2026-07-01 |
| Primary Completion | 2026-12-24 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 360 participants in total. It began in 2026-07-01 with a primary completion date of 2026-12-24.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This prospective randomized controlled study will be conducted to compare the effects of preoperative oral magnesium and intraoperative IV magnesium on the incidence and severity of emergence delirium in children undergoing adenotonsillectomy using sevoflurane anesthesia.
Eligibility Criteria
Inclusion Criteria: * Children aged 4 to 7 years * American Society of Anesthesiologist (ASA) Status I or II * Planned for an adenotonsillectomy procedure under sevoflurane general anesthesia. Exclusion Criteria: * Parents declined to participate in the trial * Behavioral changes, neurological or psychiatric problems * Anticonvulsant or sedative drugs * Physical or developmental abnormalities * Allergies to magnesium * cardiovascular, renal, bone, or gastrointestinal diseases.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07655817 clinical trial?
This trial is open to participants of all sexes, aged 4 Years or older, up to 7 Years, studying Magnesium. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07655817 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07655817 currently recruiting?
Yes, NCT07655817 is actively recruiting participants. Contact the research team at osamarehab@med.tanta.edu.eg for enrollment information.
Where is the NCT07655817 trial being conducted?
This trial is being conducted at Tanta, Egypt.
Who is sponsoring the NCT07655817 clinical trial?
NCT07655817 is sponsored by Tanta University. The trial plans to enroll 360 participants.